Roche to Present New Data at ASH 2025
Roche will present new data from its broad and innovative haematology portfolio at ASH 2025.
Key Presentations
The presentations will feature key Roche medicines, including:
- Columvi in combination with GemOx for the treatment of R/R DLBCL, approved in 49 countries.
- Venclexta/Venclyxto, being developed by AbbVie and Roche.
Based on the STARGLO data, Columvi in combination with GemOx is approved in 49 countries for the treatment of R/R DLBCL including the EU, UK, Australia and Canada.
On 2 July 2025, the US Food and Drug Administration issued a Complete Response Letter for the supplemental Biologics License Application for Columvi in combination with GemOx for this indication.
About Roche in Haematology
Roche has been developing medicines for people with malignant and non-malignant blood diseases for more than 25 years.
Author's summary: Roche presents new haematology data at ASH 2025.